Rubin Marc 4

What Happened Marc Rubin, a director of Curis, reported the acquisition on 2026-03-17 of 20 Securities (each Security = 1 share of Series B Convertible Non‑Redeemable Preferred Stock plus a Series A, Series B and Series C warrant). The Securities were sold at $1,000 each, so the purchase price was $20,000 in aggregate. The filing lists the preferred share component (20 shares) and the three warrant components (each reported as rights to 26,667 common‑share equivalents), all reported as award/acquisition (code A) derivative transactions rather than open‑market common‑stock purchases.

Key Details

• Transaction date: March 17, 2026; Form 4 filed March 18, 2026 (timely).
• Price paid: $1,000 per Security; total paid = $20,000 (20 Securities).
• Reported items:
  • 20 shares of Series B Preferred (converts to common)
  • Series A warrants: rights to ~26,667 common shares (20 × 1,333.33)
  • Series B warrants: rights to ~26,667 common shares
  • Series C warrants: rights to ~26,667 common shares
• Common‑share equivalents: each Series B Preferred converts into 1,333.33 common shares on March 20, 2026; the 20 preferred shares therefore correspond to ~26,667 common shares, and each warrant class likewise covers ~26,667 shares — total potential underlying common ≈ 106,668 shares (subject to rounding and limitations).
• Notable warrant/convertibility terms:
  • Series B Preferred automatically converts into common at 5 p.m. ET on March 20, 2026 (no additional consideration), subject to the Certificate of Designations and Beneficial Ownership Limits.
  • Series A and Series C warrants became immediately exercisable upon stockholder approval and the certificate amendment on March 17, 2026.
  • Series B warrants are immediately exercisable but include a termination/price‑reset provision tied to a clinical‑trial dosing milestone and the common share closing price (see filing).
• Shares owned after the transaction are not provided in the excerpt.

Context

• These are derivative/security acquisitions (preferred + warrants), not purchases of common stock. The preferred will convert automatically to common on March 20, 2026 (subject to limits), and the warrants give future rights to purchase common shares — they are not exercises or sales in this filing.
• The filing is informational and does not necessarily indicate the insider’s view of the stock; it documents the acquisition terms and timing.